Skip to main content

About Moberg

As of April 2019, Moberg Pharma focuses on the commercialization of its clinical pipeline with a combined peak sales potential estimated at USD 350–700 million. MOB-015 is a next generation nail fungus treatment, and BUPI is a novel treatment for oral pain relief in association with inflammation and ulceration of the oral mucous membranes (oral mucositis or OM), a serious complication of cancer treatment. Both drugs have demonstrated strong Phase 2 results which indicate that they have the potential to become market leaders in their respective niches. Phase 3 studies for MOB-015 are underway, with topline results expected towards the end of 2019 and the second quarter 2020 respectively, and two license agreements in place with leading companies in Canada and Europe.

In March 2019, Moberg Pharma divested the OTC-business to RoundTable Healthcare Partners and Signet Healthcare Partners for SEK 1.4 billion to enable a stronger focus on the pipeline, on MOB-015 in particular, while distributing significant value to the shareholders. An extraordinary dividend of 43-45 SEK per share is planned in November 2019. The divested operations comprised of marketing and distribution of OTC brands, mainly in the U.S. Each of the three key brands, Kerasal Nail®, New Skin® and Dermoplast®, are market leaders in their respective niches.

Business model

Moberg Pharma’s business model includes direct sales and sales through distributors and partners. Product development is based on innovative drug delivery and proven compounds, reducing time to market, development costs and risk compared with conventional drug development. Phase II trials for our projects are quickly initiated to evaluate the product in a limited number of patients. The selection of regulatory route is important – Moberg Pharma has experience with products that can be registered as pharmaceuticals, medical devices or cosmetics.

The business and marketing team at Moberg Pharma has solid experience in global product commercialization. The organization is supplemented with external expertise and capacity, in areas including clinical development, production and commercialization.